Dok2 mediates the CD200Fc attenuation of Aβ-induced changes in glia

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Lyons, Anthony ^a,b   Downer, Eric J ^a   Costello, Derek A ^a   Murphy, Niamh ^a   Lynch, Marina A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b St Matthews University   (United Kingdom)

Author keywords

A ; CD200; Cytokines; Dok2; Microglia; Phagocytosis; siRNA

Indexed keywords

AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; CD200 RECEPTOR; CD200FC; CD40 ANTIGEN; CD68 ANTIGEN; DOWNSTREAM OF TYROSINE KINASE 2; INTERLEUKIN 1BETA; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN SLICE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME PHOSPHORYLATION; GENE SILENCING; GLIA; HIPPOCAMPAL CA1 REGION; LONG TERM POTENTIATION; MALE; MICROGLIA; MOUSE; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

EID: 84861474441     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-107     Document Type: Article

References (38)

1. Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M, Song Y, Jenmalm M, Gorman D, McClanahan T, Liu MR, Brown MH, Sedgwick JD, Phillips JH, Barclay AN. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 2003, 171:3034-3046.
2. Wright GJ, Puklavec MJ, Willis AC, Hoek RM, Sedgwick JD, Brown MH, Barclay AN. Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 2000, 13:233-242. 10.1016/S1074-7613(00)00023-6, 10981966.
3. Barclay AN, Wright GJ, Brooke G, Brown MH. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 2002, 23:285-290. 10.1016/S1471-4906(02)02223-8, 12072366.
4. Lyons A, Downer EJ, Crotty S, Nolan YM, Mills KH, Lynch MA. CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4. J Neurosci 2007, 27:8309-8313. 10.1523/JNEUROSCI.1781-07.2007, 17670977.
5. Cox FF, Carney D, Miller AM, Lynch MA. CD200 fusion protein decreases microglial activation in the hippocampus of aged rats. Brain Behav Immun 2011, PMID:22041297.
6. Koning N, Swaab DF, Hoek RM, Huitinga I. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions. J Neuropathol Exp Neurol 2009, 68:159-167. 10.1097/NEN.0b013e3181964113, 19151626.
7. Costello DA, Lyons A, Denieffe S, Browne TC, Cox FF, Lynch MA. Long term potentiation is impaired in membrane glycoprotein CD200-deficient mice: a role for Toll-like receptor activation. J Biol Chem 2011, 286:34722-34732. 10.1074/jbc.M111.280826, 3186410, 21835925.
8. Lyons A, McQuillan K, Deighan BF, O'Reilly JA, Downer EJ, Murphy AC, Watson M, Piazza A, O'Connell F, Griffin R, Mills KH, Lynch MA. Decreased neuronal CD200 expression in IL-4-deficient mice results in increased neuroinflammation in response to lipopolysaccharide. Brain Behav Immun 2009, 23:1020-1027. 10.1016/j.bbi.2009.05.060, 19501645.
9. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, Barclay AN, Sedgwick JD. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000, 290:1768-1771.
10. Wang XJ, Ye M, Zhang YH, Chen SD. CD200-CD200R regulation of microglia activation in the pathogenesis of Parkinson's disease. J Neuroimmune Pharmacol 2007, 2:259-264. 10.1007/s11481-007-9075-1, 18040859.
11. Deckert M, Sedgwick JD, Fischer E, Schluter D. Regulation of microglial cell responses in murine Toxoplasma encephalitis by CD200/CD200 receptor interaction. Acta Neuropathol 2006, 111:548-558. 10.1007/s00401-006-0062-z, 16718351.
12. Broderick C, Hoek RM, Forrester JV, Liversidge J, Sedgwick JD, Dick AD. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am J Pathol 2002, 161:1669-1677. 10.1016/S0002-9440(10)64444-6, 1850781, 12414514.
13. Liu Y, Bando Y, Vargas-Lowy D, Elyaman W, Khoury SJ, Huang T, Reif K, Chitnis T. CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. J Neurosci 2010, 30:2025-2038. 10.1523/JNEUROSCI.4272-09.2010, 2837938, 20147531.
14. Gorczynski RM, Chen Z, Lee L, Yu K, Hu J. Anti-CD200R ameliorates collagen-induced arthritis in mice. Clin Immunol 2002, 104:256-264. 10.1006/clim.2002.5232, 12217336.
15. Gorczynski RM, Chen Z, Yu K, Hu J. CD200 immunoadhesin suppresses collagen-induced arthritis in mice. Clin Immunol 2001, 101:328-334. 10.1006/clim.2001.5117, 11726225.
16. Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, Edwards L, Gwyer E, Sedgwick JD, Barclay AN, Hussell T. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 2008, 9:1074-1083. 10.1038/ni.1637, 18660812.
17. Mihrshahi R, Barclay AN, Brown MH. Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells. J Immunol 2009, 183:4879-4886. 10.4049/jimmunol.0901531, 2788151, 19786546.
18. Mihrshahi R, Brown MH. Downstream of tyrosine kinase 1 and 2 play opposing roles in CD200 receptor signaling. J Immunol 2010, 185:7216-7222. 10.4049/jimmunol.1002858, 2999833, 21078907.
19. Nolan Y, Campbell VA, Bolton AE, Lynch MA. Evidence of an anti-inflammatory role for Vasogen's immune modulation therapy. Neuroimmunomodulation 2005, 12:113-116. 10.1159/000083583, 15785113.
20. Minogue AM, Lynch AM, Loane DJ, Herron CE, Lynch MA. Modulation of amyloid-beta-induced and age-associated changes in rat hippocampus by eicosapentaenoic acid. J Neurochem 2007, 103:914-926. 10.1111/j.1471-4159.2007.04848.x, 17711425.
21. Simelyte E, Criado G, Essex D, Uger RA, Feldmann M, Williams RO. CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. Arthritis Rheum 2008, 58:1038-1043. 10.1002/art.23378, 18383359.
22. Zhang S, Cherwinski H, Sedgwick JD, Phillips JH. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol 2004, 173:6786-6793.
23. Jenmalm MC, Cherwinski H, Bowman EP, Phillips JH, Sedgwick JD. Regulation of myeloid cell function through the CD200 receptor. J Immunol 2006, 176:191-199.
24. Shinohara H, Inoue A, Toyama-Sorimachi N, Nagai Y, Yasuda T, Suzuki H, Horai R, Iwakura Y, Yamamoto T, Karasuyama H, Miyake K, Yamanashi Y. Dok-1 and Dok-2 are negative regulators of lipopolysaccharide-induced signaling. J Exp Med 2005, 201:333-339. 10.1084/jem.20041817, 2213020, 15699069.
25. Lyons A, Griffin RJ, Costelloe CE, Clarke RM, Lynch MA. IL-4 attenuates the neuroinflammation induced by amyloid-beta in vivo and in vitro. J Neurochem 2007, 101:771-781. 10.1111/j.1471-4159.2006.04370.x, 17250684.
26. Combs CK, Karlo JC, Kao SC, Landreth GE. beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 2001, 21:1179-1188.
27. McQuillan K, Lynch MA, Mills KH. Activation of mixed glia by Abeta-specific Th1 and Th17 cells and its regulation by Th2 cells. Brain Behav Immun 2010, 24:598-607. 10.1016/j.bbi.2010.01.003, 20060887.
28. Hensley K. Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J Alzheimers Dis 2010, 21:1-14.
29. Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 2005, 25:8240-8249. 10.1523/JNEUROSCI.1808-05.2005, 16148231.
30. Paradisi S, Matteucci A, Fabrizi C, Denti MA, Abeti R, Breit SN, Malchiodi-Albedi F, Mazzanti M. Blockade of chloride intracellular ion channel 1 stimulates Abeta phagocytosis. J Neurosci Res 2008, 86:2488-2498. 10.1002/jnr.21693, 18438938.
31. Clarke RM, Lyons A, O'Connell F, Deighan BF, Barry CE, Anyakoha NG, Nicolaou A, Lynch MA. A pivotal role for interleukin-4 in atorvastatin-associated neuroprotection in rat brain. J Biol Chem 2008, 283:1808-1817.
32. Kelly L, Grehan B, Chiesa AD, O'Mara SM, Downer E, Sahyoun G, Massey KA, Nicolaou A, Lynch MA. The polyunsaturated fatty acids, EPA and DPA exert a protective effect in the hippocampus of the aged rat. Neurobiol Aging 2011, 32:e2311-2318.
33. Chitnis T, Imitola J, Wang Y, Elyaman W, Chawla P, Sharuk M, Raddassi K, Bronson RT, Khoury SJ. Elevated Neuronal Expression of CD200 Protects Wlds Mice from Inflammation-Mediated Neurodegeneration. Am J Pathol 2007, 170:1695-1712. 10.2353/ajpath.2007.060677, 1854964, 17456775.
34. Meuth SG, Simon OJ, Grimm A, Melzer N, Herrmann AM, Spitzer P, Landgraf P, Wiendl H. CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing. J Neuroimmunol 2008, 194:62-69. 10.1016/j.jneuroim.2007.11.013, 18164423.
35. Zhang S, Wang XJ, Tian LP, Pan J, Lu GQ, Zhang YJ, Ding JQ, Chen SD. CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease. J Neuroinflammation 2011, 8:154. 10.1186/1742-2094-8-154, 3226566, 22053982.
36. Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue LF. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp Neurol 2009, 215:5-19. 10.1016/j.expneurol.2008.09.003, 2765462, 18938162.
37. Costello DA, O'Leary DM, Herron CE. Agonists of peroxisome proliferator-activated receptor-gamma attenuate the Abeta-mediated impairment of LTP in the hippocampus in vitro. Neuropharmacology 2005, 49:359-366. 10.1016/j.neuropharm.2005.03.009, 15993441.
38. Lynch AM, Loane DJ, Minogue AM, Clarke RM, Kilroy D, Nally RE, Roche OJ, O'Connell F, Lynch MA. Eicosapentaenoic acid confers neuroprotection in the amyloid-beta challenged aged hippocampus. Neurobiol Aging 2007, 28:845-855. 10.1016/j.neurobiolaging.2006.04.006, 16714069.